Joint Operations Medical presents knee osteoarthritis treatment at global conferences

Joint Operations Medical GmbH, operating under the Arthrosamid® brand, actively participated in eight major orthopaedic conferences globally during the first half of 2026. The company's presence spanned events such as the British Patellofemoral Society Annual Meeting, WCO in Prague, and OARSI in Miami.

At these gatherings, the company presented research findings and clinical data on its polyacrylamide hydrogel injection treatment for knee osteoarthritis. Presentations highlighted the hydrogel's role in improving joint function and patient outcomes. Additionally, a white paper on advancing osteoarthritis care was launched.

The conference participation provided a platform for sharing scientific advancements and engaging with medical professionals. These events underscored discussions surrounding evolving osteoarthritis treatments and therapeutic innovations within the orthopaedics sector.

Joint Operations Medical GmbH continues its commitment to advancing and disseminating knowledge on osteoarthritis management in collaboration with industry experts at future events.